Objective: The aim of this study was to investigate the potential of mindfulness-based stress reduction (MBSR) as a treatment for chronic primary insomnia.
INTRODUCTION
It is estimated that close to one in 10 adults in the United States has chronic insomnia, with higher rates among women, older adults, and clinical populations. 1, 2 Chronic insomnia is associated with many comorbidities; increased risks for depression, hypertension, and heart disease; and has a pervasive, negative impact on individuals' quality of life. [3] [4] [5] [6] [7] Insomnia also has a profoundly negative impact on the economy through lost productivity and increased healthcare costs. 8, 9 Although both cognitive behavioral therapy and pharmacotherapy (PCT) have been shown to improve sleep outcomes, most people do not obtain effective insomnia treatment. 3, 8, 10 Complementary and alternative medicine (CAM) approaches have the potential to reduce, at least in part, the gap between the prevalence of chronic insomnia and the number of patients effectively treated. In 2007, 1.4% of adults in the United States reported using CAM approaches to treat insomnia or difficulty sleeping. 11 However, no CAM treatments have conclusively established efficacy and safety for treatment of chronic insomnia. 1 Mindfulness-based stress reduction (MBSR) is a mind-body based CAM intervention that has been identified as a potential therapy for insomnia but lacks evidence from adequately powered and controlled clinical trials. mindfulness training, participants learn to view their thoughts as mental events and not facts. In this way, participants become exposed to the positive and negative content of their thoughts and do not get absorbed in thought, caught up in planning for the future, or worrying about the past. The practice of mindfulness throughout the day is posited to enable one to skillfully respond to stressors with appropriate actions, as opposed to reacting "on automatic pilot" with conditioned responses that can be emotionally arousing or harmful. By "breaking up" cycles of rumination and worry, mindfulness is hypothesized to reduce "verbal overregulation" and facilitate the disengagement necessary to fall asleep. 14 Mindfulness programs have been found to improve sleep quality in longitudinal studies of patients with medical or psychiatric illnesses. 12 Patients with cancer 15 and recipients of organ transplants 16, 17 reported significantly improved Pittsburgh Sleep Quality Index (PSQI) scores after attending an MBSR program, with medium-to-large effect sizes for MBSR (d ϭ 0.60-0.65). Among the transplant recipients, findings supported a dose-response relationship between home meditation practice and sleep quality: more practice was associated with a greater decline in PSQI scores (correlation, Ϫ0.47; P ϭ .04). 16, 17 Mindfulness-based stress reduction was used by Bootzin and Stevens 18 in a multicomponent intervention to improve sleep and reduce substance abuse recidivism among adolescents. Improvements in several sleep parameters measured by diary were found, and actigraphy results were marginally significant (P ϭ .06) for improved total sleep time (TST). Two studies of mindfulness-based cognitive therapy (MBCT), a depression-relapse prevention program modeled after MBSR that shares its mindfulness training techniques, reported improved sleep outcomes for patients with mood and anxiety disorders. 19, 20 The impact of MBSR on patients with primary sleep disorders has not been investigated.
Research Objective
The objective of this study was to determine if MBSR could achieve clinically meaningful reductions in insomnia severity in patients with primary chronic insomnia. This trial was designed to be a pilot for a future full-scale comparative effectiveness trial of MBSR as a treatment for chronic insomnia. The main research questions for this pilot were as follows:
1. Will MBSR impact sleep quality and quantity as measured by sleep diary, actigraphy, and standardized scales at eight weeks, and if so, are impacts sustained at fivemonth follow-up? 2. Are the magnitudes of MBSR effects on sleep outcomes generally comparable to the impact of nightly use of a Food and Drug Administration (FDA)-approved sedative hypnotic? 3. Will MBSR show benefit to health-related quality of life and reduce activity impairment among chronic insomnia patients? 4. Are relationships between sleep outcomes and meditation practice time consistent with a dose-response relationship?
METHODS

Study Design and Sample Size
This was a two-group randomized, controlled pilot study. Patients were stratified by gender and then randomized 2:1 to MBSR (n ϭ 20) or PCT (n ϭ 10) by using computer-generated randomization schedules with small randomly permuted blocks to ensure balance within strata and across study arms ( Figure 1 ). The study coordinator was notified by e-mail of random assignments after baseline data collection, and then the coordinator notified the patient and other study personnel. Outcomes were measured at three time points: prerandomization baseline, end of the active intervention period, and five-month follow-up. The pilot sample was chosen to be sufficient to detect moderate to large treatment effects within the MBSR group (effect size, 0.68, assuming n ϭ 19 due to 10% dropouts, a precorrelation-postcorrelation of 0.50, 80% power, and two-sided 0.05 ␣). 21 Based on the pooled baseline standard deviations, this effect size corresponds to 2.3, 1.7, 6.3, and 4.2 points on the Insomnia Severity Index (ISI); PSQI; Short Form-12 version 2 Physical and Mental Health Component Summaries; respectively, or 18.9 minutes for sleep latency measured by sleep diary.
The study protocol was approved by the institutional review panels of the University of Minnesota and the Hennepin County Medical Center, site of the Minnesota Regional Sleep Disorders Center, and all patients completed written informed consent.
Patients
Patients were recruited between July 2007 and September 2008 through newspapers, Internet, and radio advertisements, and by clinician referral. Inclusion criteria were age 18 to 65 years, ability to read and speak English, and a diagnosis of primary chronic insomnia. Chronic insomnia was defined as difficulty initiating or maintaining sleep despite adequate opportunity for sleep, with related daytime dysfunction on three or more nights a week for the past six months or longer, consistent with the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Text Revision (307.42) 22 and International Classification of Sleep Disorders.
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A four-part screening protocol applied consensus diagnostic criteria for primary insomnia. 24 Telephone screening was followed by a structured psychiatric interview, 25 completion of a screening sleep diary, and a history and physical examination conducted by a sleep physician. 24, 26, 27 Persons with medical conditions, mental disorders, or different sleep disorders suspected of being directly related to the insomnia were excluded. Those using prescription or nonprescription sleep aids prior to enrollment could be included if willing to discontinue use for the duration of the study. Patients (n ϭ 20) who reported use of prescription or over-the-counter sleep aids at the first stage of the screening process were required to discontinue use prior to continuation in screening. Washout periods varied, but the minimum period of discontinuation prior to baseline sleep data collection was 10 days. Of the 158 persons who initially contacted the study, 46 declined to be screened (Figure 1 ). Eighty-two persons were excluded: 69 during telephone screening and 13 following the psychiatric interview or sleep physician examination. Among the exclusions were 11 people who would not accept the possibility of being randomized to PCT.
Interventions
Mindfulness-based stress reduction was provided through the Center for Spirituality and Healing at the University of Minnesota and conducted using the standard format of eight weekly, 2.5 hours classes, and a daylong retreat. 28 Meditation techniques included the body scan, standing, sitting, and walking meditations, and gentle hatha yoga. A six-hour silent retreat was held on the weekend between weeks six and seven. Home practice expectations were 45 minutes of meditation per day at least six days a week for eight weeks, followed by 20 minutes per day for three months. The MBSR teacher completed basic and advanced MBSR instructor training at the Center for Mindfulness in Medicine, Health Care and Society, 29 and followed the class-by-class outline of activities, readings, and homework assignments in the 2003 MBSR instructor's manual. 30 Whereas readings on sleep and sleep stress from Full Catastrophe Living 13 are optional in the standard MBSR program, for this study those readings were assigned for week two. To promote treatment fidelity, study staff distributed the assignments and class handouts in a workbook developed by the Center for Spirituality and Healing at the University of Minnesota. 31 Participants were given audio recordings of guided meditations for home use.
Pharmacotherapy was selected as the control for this study because it is the most readily available, proven treatment for chronic insomnia, and the extensive testing required for FDA approval supports the reproducibility of efficacious impact when delivered in a standard dose. Our PCT arm was modeled on clinical practice. It is standard and common practice to prescribe eszopiclone on a nightly basis for a number of months during the initial management of chronic primary insomnia. The PCT treatment consisted of three milligrams of eszopiclone (LUNESTA (R), Sepracor, Inc.) nightly for eight weeks, followed by use as needed for three months. Patients initially met in a small group with the sleep physician, who gave instructions for properly taking medication and explained potential side effects. Patients were then given their first 30-day supply of three-milligram eszopiclone tablets in a bottle with a Medication Event Monitoring System cap (MEMS cap). Refills were mailed. Patients were instructed to pour refill tablets into the MEMS capped bottle when taking their next pill. The MEMS cap records a date/time stamp when opened but provides no feedback to the patient. Patients were told that the MEMS cap records adherence.
Adherence was also tracked electronically in the MBSR arm. Participants were instructed to turn on a logger when they began a meditation or yoga session and to switch the logger off at the end of the session. The logger, a pocket-sized, battery-operated recording device (HOBO data logger, Onset Computer Corporation, Pocasset, MA) stores a date/time stamp whenever it is switched on or off and provides no feedback to the patient. Patients were told that the logger records practice time.
A 10-minute presentation about sleep hygiene was given at the first MBSR class and at the PCT group meeting with the sleep physician. Sleep hygiene booklets developed at the National Institutes of Health 32 were distributed to all patients to standardize knowledge of sleep hygiene across treatment arms. Adverse events were monitored in both treatment arms. Monitoring calls were made weekly during the first eight weeks, tapered to biweekly in month three, and once in months four and five. A call one month after study completion monitored for problems with drug discontinuation (PCT arm only). In the MBSR arm, monitoring calls also promoted regular meditation practice. The monitoring calls were made by study research staff, not the MBSR teacher or sleep physician. In cases where adverse events were reported in the PCT arm, the sleep physician was consulted. No adverse events were reported in the MBSR arm.
Measures
Sleep diaries, wrist actigraphy, and self-report questionnaires were used to measure outcomes. Participants kept a standard sleep diary and wore a wrist actigraph on their nondominant wrist for 14 days prior to the start of the study interventions, during the final two weeks of the active intervention period, and for two weeks during month five (sleep diary only). The sleep diary variables are averages at each interval and include TST, sleep onset latency (SOL), wake after sleep onset (WASO), and sleep efficiency (SE, time asleep divided by time in bed). These variables were also objectively estimated using actigraphy recordings (Actiwatch AW64, analyzed by Actiware Sleep, version 3.4, Mini Mitter Company, Inc, Bend, OR). 26 Benchmarks for "poor sleep" are SOL or WASO of 30 minutes or more, TST less than six hours, and SE under 85%.
Standardized measures of sleep and health-related quality of life were reported in questionnaires completed at home and returned by mail at prerandomization baseline, eight weeks, and five months. The seven-item ISI assesses the current severity of insomnia symptoms, sleep dissatisfaction, daytime impacts, and distress about sleep difficulties. 33 Each ISI item is rated on a five-point scale, with total scores ranging from zero to 28. Insomnia Severity Index clinical cut points are defined as follows: no insomnia (zero to seven), subthreshold insomnia (eight to 14) , moderate insomnia (15) (16) (17) (18) (19) (20) (21) , and severe insomnia (22) (23) (24) (25) (26) (27) (28) . Response to treatment on the ISI has been defined as a change of seven or more points from baseline, and remission as reduction to a score less than eight. 34 The PSQI measures sleep quality and quantity, based on recall of sleep behaviors in the past month. 35, 36 The 19 PSQI questions measure seven domains of sleep: quality, latency, duration, efficiency, disturbances, use of sleep medications, and daytime dysfunction. Domain scores are coded from zero to three, and an overall PSQI score is obtained by summing across domains. The overall PSQI score can range from zero to 21, three points constitutes a meaningful change, and a score greater than five has been proposed to identify poor sleepers.
The Dysfunctional Beliefs and Attitudes about Sleep measures perceived consequences of insomnia, helplessness and worry about sleep, sleep expectations, and physical and emotional attributions that are hypothesized to perpetuate insomnia. 27, 37 Sixteen statements are rated on a zero-to-10 scale and averaged, with higher scores indicating more dysfunction. The Sleep Self-Efficacy Scale consists of nine items that measure confidence in perceived ability to engage in behaviors that influence sleep. 38 Item responses were scored on a zero-to-10 scale and then averaged, with higher scores indicating greater confidence. 39 Secondary outcomes include widely used, well-validated measures of anxiety, depression, health-related quality of life, and activity limitation. The 20-item State-Trait Anxiety Inventory, state version, was used to measure anxiety at the present time. 40 Scores range from 20 to 80, and cut points have been proposed for mild (Ͻ40), moderate (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) , and severe (Ն60) anxiety symptoms. Depression symptom intensity was measured by the 20-item Center for Epidemiologic Studies Depression Scale; scores range from zero to 60, and a score of 16 or higher has been proposed to identify clinically meaningful depression symptoms. 41 Health-related quality of life was measured by mental and physical component summary scores of the Short Form-12, version 2. 42 The Short Form-12 items measure the eight aspects of health and well-being that form the SF-36 health profile: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, energy/fatigue, social functioning, role limitations due to emotional health, and mental health (psychological distress and emotional well-being). The Short Form-12 mental component and physical component summaries are unbiased, close approximations to their SF-36 counterparts. 43 Activity impairment was assessed by a question that asks, "In the last 7 days, to what extent did insomnia affect your ability to carry out normal daily activities, not including your job?" with responses marked on an 11-point scale, with zero being "Insomnia did not affect my daily activities," to 10 being "Insomnia did not permit me to do daily activities at all." 44 It is expressed as an impairment percentage, with higher scores indicating more impairment.
Statistical Analysis
The balance between treatment groups on baseline variables was examined using descriptive statistics, Fisher exact tests, and Mann-Whitney U tests. Changes from baseline to eight weeks and to five months were tested within treatment groups by using paired t tests or by Wilcoxon tests when normality could not be assumed. 45 Cohen's d effect sizes were estimated by the difference between follow-up and baseline values divided by the pooled standard deviation at baseline. 21 Cohen's criteria for small, medium, and large treatment effects are 0.2, 0.5, and 0.8, respectively. 46 Repeated measures analyses of variance were conducted to compare outcomes between groups over time, although only very large differences would be detectable in this pilot study. Clinical importance was estimated by examining "percent recovered" in conjunction with using the reliable change index, 47 which requires that a patient's outcome score moves from the abnormal to the normal range, and moreover, that the amount of change exceeds measurement error, based on the reliability of the outcome scale.
For all efficacy analyses, three patients were omitted: one patient randomized to PCT who refused to take the study medication; one patient who withdrew after randomization to MBSR, failing to return baseline data and without attending any intervention sessions; and one patient who attended only four MBSR classes (attendance at five or more classes is the benchmark for MBSR course completion 48 ). Sample sizes are indicated for each analysis; missing data were not imputed. Adherence and treatment satisfaction were summarized using descriptive statistics. Meditation practice time was correlated with change in primary outcomes by using Spearman's rho correlations. Descriptive statistics were obtained using SPSS 17.0 (SPSS Inc, Chicago, IL). All other statistical analyses were conducted using SAS 9.1 (SAS Institute Inc, Cary, NC).
RESULTS
The sample consisted of 22 women and eight men, who ranged in age from 19 to 65 years and were well educated ( Table 1) . The majority (80%) were working full or part-time. History of insomnia complaints ranged from one to 30 years, with a median duration of six years. At screening, two thirds of the patients were using sleep medications, either prescription or over the counter, and 20% had previously tried eszopiclone. Medical comorbidities were common, with almost half the sample (46%) reporting two or more. Baseline characteristics were reasonably balanced across study arms; however, the number of patients who reported a history of depression or an anxiety disorder was somewhat higher in the MBSR arm.
Sleep diaries completed for 14 days prior to randomization confirmed poor sleep: mean SOL, 44.5 minutes; mean WASO, 55.5 minutes; mean TST, 6.3 hours; and mean SE, 75.3%. Actigraphy-derived averages for this period were similar to the diary values for TST (mean 6.4 hours), WASO (mean 58.5 minutes), and SE (77%), and somewhat shorter than the diary values for SOL (mean 34.6 vs 44.5 minutes, Mann-Whitney U test; P ϭ .05). Self-report scales also confirmed sleep problems at baseline. The average score on the ISI was consistent with moderate insomnia (mean, 17.1, SD ϭ 3.34; ISI range, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , and all patients scored above seven, the cutoff for no insomnia. All participants were in the PSQI "poor sleep" range at baseline, and the average PSQI score was 11.6 (SD ϭ 2.53, range, eight to 18). No significant differences were found at baseline on actigraphy-derived sleep parameters or on the standardized sleep scales between treatment groups; however, based on diary reports, WASO was perceived to be somewhat shorter (46.6 vs 72.6 minutes; P ϭ .11) and SE somewhat higher (77.3% vs 71.7%; P ϭ .07) in the group randomized to MBSR than in the PCT arm.
No statistically significant differences were found between MBSR and PCT groups over time on sleep or quality of life outcomes, based on repeated measures analyses of variance. Lack of difference does not confirm equivalence, however, as the sample size was not sufficient to establish the noninferiority of MBSR to PCT for sleep treatment. Consistent with the pilot objectives, changes within each group are described below. 
Sleep Diary Outcomes
Sleep diaries were completed every morning for two weeks at three time points: pretreatment baseline, the end of the active intervention period, and the end of follow-up. Sleep diary results are shown in Table 2 . In the MBSR arm, diary-based SOL, WASO, and SE significantly improved from baseline to the end of the active intervention period, providing medium-sized treatment effects (d ϭ Ϫ0.57, Ϫ0.46, and 0.61, respectively; P Ͻ .01, all). A treatment impact of MBSR on TST emerged by 5-month follow-up. Whereas the impact on WASO appeared to wane, it is notable that other treatment effects in the MBSR arm increased with longer follow-up; medium to large treatment effects for TST, SOL, and SE (d ϭ 0.69, Ϫ0.80, and 0.79, respectively; P Ͻ .01, all) by five months. In the PCT arm, diary-based TST, WASO, and SE significantly improved from baseline to the end of the active intervention period, and these improvements were sustained, with large treatment effects from baseline to five months (d ϭ 0.92, Ϫ0.97, and 1.29, respectively). Although not statistically significant, there is a suggestion that MBSR may impact SOL more than PCT (mean change at follow-up: Ϫ22.2 vs Ϫ4.65 minutes for MBSR vs PCT).
Actigraphy Outcomes
Actigraphs were worn at two points in time, in tandem with completion of the sleep diaries at prerandomization, and the end of the active intervention period. Actigraphy results are shown in Table 3 . A statistically significant 8.9-minute decrease in actigraphy-derived SOL was found within the MBSR arm (d ϭ Ϫ0.31; P ϭ .04), consistent with the perceptions of shorter times to fall asleep that these patients recorded in their diaries. Other actigraphy changes in the MBSR arm were small (d Ͻ 0.22 ) and not statistically significant. In the PCT arm, however, actigraphy-derived TST and SE parameters significantly improved (d ϭ 0.63 and 0.52, respectively; P Ͻ .05, both), and although not statistically significant, the average WASO decreased 14.8 minutes.
Standardized Sleep Scales and Quality Of Life Measures
Standardized sleep scales are shown in Table 4 . The MBSR group reported large, statistically significant improvements from baseline to follow-up on all self-reported sleep measures at eight weeks and at five months ( d range, 0.8-2.4; P Ͻ .01, all). Large treatment impacts were also noted in the PCT arm, although due to the smaller sample size, some results were not statistically significant. Figures 2 and 3 depict the individual trajectories of change for the ISI and PSQI by treatment group; reduced symptoms are visible by eight weeks, and many patients reported continued improvement through the end of follow-up.
Health-related quality of life results are shown at the bottom of Table 4 . Insomnia-related activity impairment was significantly reduced in the MBSR group at both eight weeks and five months (P Ͻ .01; d ϭ Ϫ1.1 and Ϫ0.80, respectively). The impact on activity impairment in the PCT arm was similar but not significant due to the smaller sample size. By five-month followup, symptoms of anxiety and depression decreased and mental health scores increased in both groups, but these changes were not statistically significant. The improvement in mental health approached significance in both arms (P ϭ .06 and P ϭ .08, respectively) with mean changes of 4.6 to 5.8 points, respec- tively, exceeding accepted criteria for clinically important change.
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Recovery From Chronic Insomnia All study participants met criteria for insomnia and poor sleep at baseline. Numbers of patients who experienced a reliable improvement and no longer met these criteria are shown in Table 5 . By five months, over half the MBSR patients had recovered, based on the ISI and PSQI. Moreover, no patient experienced a clinically important deterioration in his or her insomnia, defined as an increase of seven points on the ISI. Notably, about half the patients in the MBSR arm whose recorded sleep efficiency was below 85% at baseline had a reliable improvement by five-month follow-up (seven of 13), and all but one of the MBSR patients whose TST averaged less than six hours at baseline was reliably sleeping more than six hours per night at follow-up (four of five). Although not statistically significant, it is interesting to note that the rates of recovery from poor sleep, as measured by the PSQI, were considerably higher following MBSR than PCT at eight weeks and at five months.
Adherence and Treatment Satisfaction
The study was completed with two MBSR programs (n ϭ 9, n ϭ 11). Eighteen of 20 patients (90%) attended at least five MBSR classes, meeting the benchmark for course completion. Ten MBSR patients attended all eight classes, and 16 of 20 attended the all-day retreat. In their follow-up questionnaires, 14 of 18 MBSR patients in the outcome analyses (78%) reported no use of sleep medications (prescription or over the counter), two reported using sleep medications less than once a week, and two reported use once or twice a week.
Nine of 10 patients randomized to PCT took their assigned medication. Based on analysis of the electronic pill monitors (MEMS caps) over the first eight weeks, three patients were 100% compliant with nightly dosing, two had over 90% compliance, and four took eszopiclone four to six nights each week. By the final study month, two patients discontinued eszopiclone completely, and these patients reported using no other sleep medications. Six PCT patients continued use of eszopiclone through the last month of follow-up: two maintained nightly dosing, three took a dose four to six nights a week, and one used eszopiclone an average of two nights a week. One patient did not submit medication use data at five months.
Meditation home practice time was calculated based on electronic loggers submitted by 17 patients who completed MBSR. The average home practice time was 23.7 (SD, 11.2) minutes per day during the eight-week active intervention period. This represents 61% of the home practice expectation during this period (eg, 45 minutes per day, six days a week); however, time spent meditating during MBSR classes would boost these averages. Sixteen MBSR patients reported practice throughout follow-up, with an average of 21.8 minutes of practice per day during months three thru five, consistent with follow-up practice expectations of 20 minutes per day. The median number of days practiced in the final week of the study was four days. Reductions in dysfunctional beliefs about sleep scores and activity limitation due to insomnia from baseline to month five were significantly predicted by home practice during the active intervention period (Spearman's rho correlations, 0.62 and 0.71, respectively; P Ͻ .02). Correlations with changes in other measures were smaller and not significant. Treatment satisfaction and treatment preferences were evaluated at five-month follow-up. Treatment satisfaction was rated on a zero to 10-point scale, from "very dissatisfied" to "very satisfied." The satisfaction scores in the MBSR group were high, with a mean of 8.8. The average satisfaction score in the PCT group was lower, with a mean of 6.1. Treatment preference was ascertained by recall, using the question, "When you joined this study which treatment did you hope to be assigned to?" In the MBSR arm, 14 indicated MBSR, two PCT, and two no preference. In the PCT arm, five indicated MBSR, two PCT, and one no preference. There were no unexpected, serious adverse events related to the interventions in this trial. One PCT patient was switched from eszopiclone to controlled-release zolpidem during the first month of treatment because of persistent complaints of an extremely unpleasant after-taste. Other side effects reported in the PCT arm included excessive sleepiness, headache, and dizziness. No adverse events related to MBSR were reported.
DISCUSSION
This study provides initial evidence for the efficacy of a complementary and alternative treatment modality, MBSR, as a viable treatment for chronic insomnia as measured by sleep diary, wellvalidated sleep scales, actigraphy, and measures of remission and Sample excludes three patients: one refused to take study medication, one refused to attend MBSR, one completed fewer than five MBSR classes. a Sample sizes for baseline and for change to eight weeks (MBSR, n ϭ 18; PCT, n ϭ 9). b Sample size for change to five months vary due to missing data (MBSR, n ϭ 17-18; PCT, n ϭ 7-8). *P Ͻ .05. **P Ͻ .01. ***P Ͻ .001.
clinical recovery. Our results suggest that MBSR, when combined with a brief sleep hygiene presentation, is able to achieve reductions in insomnia symptoms and improvements in sleep quality comparable to regular use of an FDA-approved sedative hypnotic. To our knowledge, this is the first study to employ a rigorous randomized study design to compare the efficacy of MBSR to PCT in patients with primary chronic insomnia. Patients who completed five or more MBSR classes reported sleep diary changes that were large and clinically meaningful: TST increased by over 30 minutes, SOL reduced by over 20 minutes, and sleep efficiency increased to 84.5% by five-month follow-up. Notably, a statistically significant reduction in actigraphy-derived SOL of about nine minutes supported the patients' self-reports. Moreover, half of the patients randomized to MBSR met stringent criteria for recovery from insomnia at the end of the study, and average treatment satisfaction scores were high. Whereas patients in the PCT arm obtained similar benefits to sleep outcomes, their treatment satisfaction scores were not high, and several patients reported adverse events.
Impacts found following MBSR compare favorably to outcomes reported from trials of cognitive-behavioral therapy for patients with chronic or persistent insomnia. Morin et al 34 recently reported the results of a trial of where adults with persistent insomnia were randomized to six weeks of group cognitivebehavioral therapy. These patients improved from an average ISI score of 17.26 at baseline to an average of 8.11 at six-month follow-up; sleep efficiency measured by diary improved from 69% to 82.4%, and large improvements in SOL and time awake after sleep onset were also found. Our finding of durable improvements to sleep outcomes from MBSR over follow-up is consistent with results reported by Edinger et al 51 from their seminal trial of cognitive-behavioral therapy primary insomnia.
Our findings build upon positive results from several longitudinal studies of mindfulness-based treatment approaches with insomnia patients. Three uncontrolled studies with a total of 56 patients and one wait-list controlled trial with 52 patients reported reductions in insomnia symptoms and improvements on other sleep outcomes in patients with mood and/or anxiety disorders following MBCT. Ree and Craigie 20 included the ISI in a study of MBCT for psychiatric outpatients with insomnia and reported significant improvement (ISI, d ϭ 0.84) for 23 patients following the program, and benefits maintained at three-month follow-up. Heidenreich et al 52 reported that 14 patients with refractory chronic insomnia comorbid with other mental disorders showed pre-MBCT to post-MBCT improvements in TST and sleep latency measured by sleep diary, and a decline in dysfunctional thoughts about insomnia. Yook et al 53 reported PSQI scores were significantly decreased among 19 patients with anxiety disorders and insomnia after an eight-week MBCT program. Britton et al 54 studied the sleep outcomes of seven women with insomnia following an abbreviated MBSR program and found that WASO measured by sleep diary was reduced. In a subsequent wait list-controlled trial, Britton 19 enrolled adults with insomnia comorbid with depression and randomized them to an eight-week MBCT program or a wait list. Compared to controls (n ϭ 17), MBCT participants' sleep diary reports (n ϭ 25) indicated significantly shorter WASO and trends for decreased SOL and decreased awakenings, adjusted for use of antidepressants. 19 These studies, all of which found reductions in one or more measures of mood or cognition (depression, anxiety, worry, or rumination) as well as sleep improvements, complement the growing literature on the health benefits of mindfulness training with MBSR or MBCT. 28, 55 These findings, in conjunction with the results of the present study, suggest that mindfulness training has potentially broad application for improving insomnia and closely associated problems that may perpetuate insomnia-symptoms of anxiety and depression.
An exciting approach undertaken by Ong et al 56 adds mindfulness training to cognitive-behavioral therapy for insomnia. These investigators developed a six-week program that combined mindfulness training with cognitive-behavioral therapy. Following the combined program, patients with psycho-physiological insomnia (N ϭ 30) reported lower total wake time (a combination of SOL, WASO, and terminal wakefulness), increased SE (from 78.5% to 87.6%), reduced insomnia severity (ISI mean, 14.9 preprogram, 9.6 postprogram), and a reduction in dysfunctional beliefs about sleep. Long-term follow-up of a subset of patients (n ϭ 21) showed that benefits to total wake time, sleep efficiency, and ISI scores were sustained. 57 It would be fruitful in future studies to determine if cognitive-behavioral therapy for insomnia combined with mindfulness is more effective than either approach alone.
Whereas the benefit of MBSR for sleep problems has been demonstrated, the biological and psychological mechanisms responsible for these benefits are not known. The impact of mindfulness training on physiologic and emotional hyperarousal, maladaptive sleep habits, and dysfunctional attitudes and beliefs about sleep is discussed in the chapter Sleep and Sleep Stress of the text that introduced the MBSR program, Full Catastrophe Living. 13 Suggested behaviors are consistent with the recommendations of sleep hygiene and cognitive behavioral programs and include establishing a mindful presleep routine, not spending time awake in bed (eg, getting up and doing yoga or something enjoyable if unable to sleep), and switching attention from wakefulness by focusing on the breath or practicing a meditation technique. Additional work will be needed to determine which elements of MBSR are responsible for its impact on sleep. Finally, although MBSR appears to compare favorably with conventional PCT, the fact that at follow-up only half of the patients in this study met criteria for recovery from insomnia suggests that there is still considerable room for improvement in our approaches to treating insomnia. 58, 59 Strengths of our study include a rigorous randomized design and multistage screening process to eliminate individuals likely to have insomnia due to another underlying disorder. Maintaining fidelity to the standard MBSR approach, with only the inclusion of a brief, standard sleep hygiene component, should facilitate replication of our findings and enhance generalizability. In addition, the use of objective tracking technologies (MEMS caps and HOBO loggers) to obtain information on compliance substantially enriches the findings of this study. Limitations include the pilot sample size, which precluded establishing equivalence between MBSR and PCT arms, 60 and lack of additional control groups, such as a medication placebo and a behavioral attention control, to exclude the possibility that nonspecific factors such as expectancy, attention, or regression to the mean might account for the positive effects found. As eszopiclone is an FDA-approved medication for treatment of chronic insomnia, and outcomes were assessed by objective and subjective measures at several time points, we have confidence that nonspecific factors are not fully responsible for the positive impacts shown. 61 Other limitations include the homogeneity of participants in terms of educational attainment and race.
Prior research has shown that, in general, patients prefer nonpharmacologic therapies for their insomnia. 62 Following completion of the study, our study participants were queried regarding treatment satisfaction and preference; more participants preferred a treatment assignment to the MBSR group, and treatment satisfaction in this group was higher on average. This suggests that there may be a sizable proportion of individuals with chronic insomnia for whom CAM therapies such as MBSR are particularly desirable and preferred to pharmacologic interventions. Table 5 . Clinical Significance of Self-Reported Outcomes CONCLUSIONS Although the time commitment associated with participating in and practicing a behavioral intervention such as MBSR is more than with medication, our results suggest that this is not a deterrent to most of our participants. Given patient preferences, the side effects of PCT, evidence of the efficacy of MBSR, and the potential positive benefits of meditation that go beyond management of insomnia symptoms, it is important that healthcare providers be aware of the range of nonpharmacologic therapy approaches and that clinicians offer patients options that include MBSR. Future studies of MBSR for insomnia should employ larger sample sizes and longer follow-up to assess the durability of treatment impacts, and include design features that could reveal mechanisms of action and deduce the most effective components of this intervention.
